Page 2525 - Williams Hematology ( PDFDrive )

2496 Index Index 2497

Thalassemias, 725–754 clinical use, 334 generation, 1918–1919, 1919f, 1940, 1940f,
clinical features, 743–745, 744f, 744t for Langerhans cell histiocytosis, 1106, 1949, 1950f
definitions and history, 725 1107 in inflammatory response, 1979t, 2201
differential diagnosis, 568–569, 748, 749f for malignant histiocytic diseases, 1110 inhibitors, 1919, 1919t
epidemiology and population genetics, for mantle cell lymphoma, 1659t, 1660t PI3K pathway and, 1841
727–728, 727f mechanism of action, 334 in platelet activation, 2293
etiology and pathogenesis, 728–730, 729f for myelodysplastic syndromes, 1359 platelet activation and, 1834, 1836, 1845,
forms, 726, 726t for myeloma, 1750, 1752, 1752t, 1754 1919
α. See α-thalassemias pharmacology, 334 structure, 1919
β. See β-thalassemias for primary myelofibrosis, 1329 in thrombosis and hemostasis, 1979t
δ, 726, 736, 751 structure, 333f transforming growth factor β and, 1848
δβ. See δβ-thalassemias THBD, 1931–1932, 1932f Thrombin-activatable fibrinolysis inhibitor
εγδβ, 735, 745, 751 T-helper cells. See CD4+ T cells (TAFI), 1972
εωδβ, 726 (helper T cells) activation, 1935
hereditary persistence of fetal T-helper type 1 (Th1) cells, 1180, 1181f aging and, 135
hemoglobin and. See Hereditary T-helper type 2 (Th2) cells, 1180, 1181f characteristics, 1916t, 1935, 2308
persistence of fetal hemoglobin T-helper type 9 (Th9) cells, 1181f, 1182 in disseminated intravascular coagulation,
(HPFH) T-helper type 17 (Th17) cells, 1182, 2000 2206
as global health problem, 754 Theophylline, cAMP inhibition and, 404 in fibrinolysis, 2203
globin gene clusters and, 728–730, 729f Therapeutic apheresis. See Apheresis gene structure and variations, 1935–1936
hemoglobin C, 749–750 Therapy-related myeloid neoplasms plasminogen and, 2154
hemoglobin E, 750 acute myelogenous leukemia. See Acute structure, 1935, 2308
hyposplenism and, 868 myelogenous (myeloid) leukemia Thrombin-antithrombin (TAT) complexes,
i antigen and, 2340 (AML), therapy-related 2209
intermedia, 725, 753 myelodysplastic syndromes. See Thrombin receptor antagonists, 406,
laboratory features, 745–748, 746f, 747f Myelodysplastic syndrome (MDSs), 2076–2077
major, 725 therapy-related Thrombin time, 1989
minima, 725 Thiamine deficiency, 652 Thromboatherogenesis, 1092
minor, 553, 636, 725 Thiamine-responsive megaloblastic anemia, Thrombocythemia, BCR-ABL-positive, 1449
molecular basis, 730–739. See also specific 608, 652 Thrombocytopenia, 1993–2018
forms Thiazides, maternal ingestion of, effect on acquired pure amegakaryocytic, 1999
pathophysiology, 739–743 fetus and newborn, 112, 112t in acute myelogenous leukemia, 1381
abnormal iron metabolism, 742 Thienopyridines, 2074t, 2075–2076 alcohol consumption and, 1998
cellular heterogeneity, 741 6-Thioguanine in alloimmune hemolytic disease of the
clinical heterogeneity, 742–743, 743f for acute lymphoblastic leukemia, 1505, fetus and newborn, 849
coagulation defects, 742 1516, 1517 in antiphospholipid syndrome, 2240
compensatory mechanisms for anemia, for acute myelogenous leukemia, 1395t, classification, 1994t
741 1399, 1409 consultative approach to, 42–43
erythroid precursor damage, 740–741 adverse effects, 324 cyclic, 2015
imbalance globin-chain synthesis, 740 for autoimmune hemolytic anemia, definition and history, 1993–1994
infection, 742 839 diagnosis, 1740, 1994
persistent fetal hemoglobin production, mechanism of action, 323 drug-induced, 2015–2018, 2016t, 2017t,
741 megaloblastic anemia and, 606t 2077
red cell damage, 740–741 pharmacology, 323–324 etiology and pathogenesis, 1985, 1986t
splenomegaly, 742 structure, 323f gestational, 45, 121–122, 2010
pregnancy and, 126 Thiopurine methyltransferase, 316, 319t, 323, heparin-induced. See Heparin-induced
prevention of, 753–754 1516 thrombocytopenia (HIT)
prognosis, 753 6-Thiopurines, 319t, 323 in hepatic disease, 2194
sickle cell, 749 Thiotepa, 331, 331t, 332t in Hodgkin lymphoma, 1610
treatment, 362–363, 751–753, 2372 Thomsen-Friedenreich (T) antigen, 2262 hypersplenism and, 2014
Thalassic anemia, 725 Thorium dioxide, 518 hypothermia and, 2014
Thalidomide, 333–335 Thrombin, 290, 1877 immune. See Immune thrombocytopenia
for acute myelogenous leukemia, 1404 binding to fibrinogen and fibrin, 2154 (ITP)
for adult Langerhans cell histiocytosis, in disseminated intravascular coagulation, in inherited platelet disorders, 1996–1997,
1109 2200–2201 1998t. See also Platelets, disorders
adverse effects, 334, 1741, 1757 formation, 1842, 1854 interferon-induced, 1825

Kaushansky_index_p2393-2506.indd 2496 9/21/15 3:23 PM